Nanosized Technological Approaches for the Delivery of Poorly Water Soluble Drugs Delivery of poorly water soluble drugs
Iranian Journal of Pharmaceutical Sciences,
Vol. 6 Núm. 3 (2010),
1 July 2010
,
Página 149-162
https://doi.org/10.22037/ijps.v6.41266
Resumen
A major hurdle in pharmaceutical formulation is water insolubility of most of drugs affecting their stability and bioavailability. If the drug is also insoluble in organic medium, it is difficult to deliver it in a sufficiently bioavailable form and hence it is a great challenge to formulation researchers to overcome such difficulty. Although some approaches are available for enhancing the dissolution of poorly soluble
drugs, there has been certain draw backs like use of organic solvents, low drug loading and large doses. However, a new solution to poorly water soluble drug candidates is now available, i.e. nanonisation that leads to much more soluble, more biologically available and safer dosage form of poorly soluble and poorly bioavailable drugs. Controlled release of these drugs is also possible by forming nanostructured
matrices. In this article, a brief description of production methods of drug nanoparticles and commercialized methods are presented along with brief overview on second generation of drug nanocrystal (Smart crystal technology), controlled release of hydrophobic drugs and recent works thereof are also presented.
- Bioavailability
- Dissolution velocity
- Insolubility
- Saturation solubility
- Smart crystal technology
Cómo citar
Citas
[2] Merisko LE, Liversidge GG, Cooper ER. Nanosizing: a formulation approach for poorlywater-soluble compounds. Eur J Pharm Sci. 2003; 18: 113-20.
[3] Keck. CM, Müller. RH. Drug Nanocrystals of poorly soluble drugs produced by high pressure homogenization. Eur J Pharm Biopharm. 2006; 62: 3-16.
[4] Muller RH, Bohm BHL. Nanosuspensions, in emulsions & nanosuspensions for the formulation of poorly soluble drugs. Stuttgart, Germany: Medpharm Scientific Publishers, 1998; pp.149–74.
[5] Liversidge GG. Surface modified drug nanoparticles, 1992. US Patent No. 5145684.
[6] Liversidge GG, Cundy KC. Particle size reduction for improvement of oral bioavailability of hydrophobic drugs: I. Absolute oral bioavailability of nanocrystalline danazol in beagle dogs. Int J Pharm. 1995; 125: 91–7.
[7] Liversidge GG, Conzentino P. Drug particle size reduction for decreasing gastric irritancy and enhancing absorption of naproxen in rats. Int J Pharm. 1995; 125:309–13.
[8] Merisko LP, Sarpotdar J, Bruno S, Hajj L, Wei N, Peltier J, Rake JM, Shaw S, Pugh, Polin L.Formulation and antitumor activity evaluation of nanocrystalline suspensions of poorly soluble anticancer drugs. Pharm. Res. 1996;13: 272–8.
[9] Müller RH, Jacobs C, Kayser O. Nanosuspensions as particulate drug formulations in therapy:Rationale for development and what we can expect for the Future. Adv Drug Del Rev. 2001; 47: 3–19.
[10] Jacobs C, Kayser O, Müller RH. Nanosuspensions as a new approach for the formulation for the poorly soluble drug tarazepide. Int J Pharm.2000; 196: 161–4.
[11] Muller RH. Nanosuspensions: A formulation approach for poorly soluble and poorly bioavailable drugs. Handbook of Pharmaceutical Controlled Release Technology. Wise. D.L. ed. New York: Marcel Dekker Inc, 2000; pp. 345–57.
[12] Muller RH. Nanosuspension for the formulation of poorly soluble drugs, in pharmaceutical emulsion and suspension. Neilloud. F. ed. and Marti-Mestres. G. ed. New York: Marcel Dekker Inc, 2000; pp. 383–407.
[13] Scholer N. Atovaquone nanosuspensions show excellent therapeutic effect in a new murine model of reactivated toxoplasmosis. Antimicrobial Agents Chemotherapeutics. 2001; 45: 771–9.
[14] Kayser O, Olbrich C, Yardley V, Kiderlen AF, Croft SL. Formulation of amphotericin B as nanosuspension for oral administration. Int J Pharm. 2003; 254:73–5.
[15] Hecq J, Deleers M, Fanara D, Vranckx H, Amighi K. Preparation and characterization of nanocrystals for solubility and dissolution rate enhancement of nifedipine. Int J Pharm. 2005;299:167–77.
[16] Trotta M, Gallarate M, Pattarino F, Morel S. Emulsions containing partially water-miscible solvents for the preparation of drug nanosuspensions. J Control Release 2001;76:119–28.
[17] Trotta M, Gallarate M, Carlotti ME, Morel S.Preparation of griseofulvin nanoparticles from aater-dilutable microemulsions. Int J Pharm.2003;254:235–42.
[18] Dixon DJ, Bodmeier RA, Johnston KP. Polymeric materials formed by precipitation with a compressed fluid antisolvent. AIChE J. 1993;39:127–39.
[19] Reverchon E. Porta. GD. Production of antibiotic micro- and nano-particles by supercritical antisolvent precipitation. Powder Technol.1999;106:23–9.
[20] Chattopadhyay P. Gupta RB. Protein nanoparticles formation by supercritical antisolvent with enhanced mass transfer. AIChE J. 2002; 48:235–44.
[21] Hanna M.H. York P. Method and apparatus for the formation of particles. 1998. US Patent No.5851453.
[22] Subramaniam B. Methods for a particle precipitation and coating using near-critical and 5833891.
[23] Young TJ, Johnston KP, Mishima K, Tanaka H..Encapsulation of lysozyme in a biodegradable polymer by precipitation with a vapor-over-liquid antisolvent. J Pharm Sci. 2000; 88: 640–50.
[24] Turk M, Hils P, Helfgen B, Schaber K, Martin HJ, Wahl MA. Micronisation of pharmaceutical substances by the rapid expansion of supercritical solutions (RESS): A promising method to improve bioavailability of poorly soluble pharmaceutical agents. J Supercritical Fluids. 2002; 22:75–84.
[25] Young TJ, Mawson S, Johnston KP, Henriksen IB, Pace GW, Mishra AK.. Rapid expansion from supercritical to aqueous solution to produce submicron suspensions of water-insoluble drugs. Biotech. Prog. 2000; 16:402–7.
[26] Pace, GW, Vachon, MG, Quebec, Mishra, AK, Henrikson, IB, Krukonis, V. Processes to generate submicron particles of water-insoluble compounds. 2001. US Patent No. 6177103.
[27] Williams RO, Johnston KP, Young TJ, Rogers TL, Barron MK. Process for production of nanoparticles and microparticles by spray freezing into liquid. 2005. US Patent No. 6862890.
[28] Rogers T, Hu J, Yu Z, Johnston K., Williams III R. A novel particle engineering technology: Spray freezing into liquid. Int J Pharm. 2002; 242:93-100.
[29] Rogers TL, Nelsen AC, Hu J, Brown JN, Sarkari M, Young TJ, Johnston KP, Williams RO 3rd. A novel particle engineering technology to enhance dissolution of poorly water soluble drugs: Spray freezing into liquid. Eur J Pharm Biopharm. 2002;54:271–80.
[30] Rogers TL, Nelsen AC, Sarkari M, Young TJ, Johnston KP, Williams RO 3rd. Enhanced aqueous dissolution of a poorly water-soluble drug by novel particle engineering technology: Spray freezing into liquid with atmospheric freezedrying. Pharm. Res. 2003; 20:485–93.
[31] Hu J, Johnston KP, Williams RO 3rd. Spray freezing into liquid (SFL) particle engineering technology to enhance dissolution of poorly water soluble drugs: Organic solvent versus organic/aqueous co-solvent systems. Eur J Pharm Sci. 2003; 20:295–303.
[32] Hu J, Johnston KP, Williams RO 3rd. Rapid dissolving high potency danazol powders produced by spray freezing into liquid process. Int J Pharm. 2004; 271:145–54.
[33] Hu J, Johnston KP, Williams RO 3rd. Stable amorphous danazol nanostructured powders with rapid dissolution rates produced by spray freezing into liquid. Drug Dev Ind Pharm. 2004;30:695–704.
[34] Chen X, Young TJ, Sarkari M, Williams RO 3rd, Johnston KP. Preparation of cyclosporine a nanoparticles by evaporative precipitation into aqueous solution. Int J Pharm. 2002; 242:3–14.
[35] Sarkari M, Brown J, Chen X, Swinnea S, Williams RO 3rd, Johnston KP. Enhanced drug dissolution using evaporative precipitation into aqueous solution. Int J Pharm. 2002; 243:17–31.
[36] Chen X, Vaughn JM, Yacaman MJ, Williams RO 3rd, Johnston KP. Rapid dissolution of highpotency danazol particles produced by evaporative precipitation into aqueous solution. J Pharm Sci.2004; 93:1867–78.
[37] Vaughn JM, Gao X, Yacaman MJ, Johnston KP, Williams RO 3rd. Comparison of powder produced by evaporative precipitation into aqueous solution (EPAS) and spray freezing into liquid (SFL) technologies using novel Z-contrast STEM and complimentary techniques. Eur J Pharm Biopharm. 2005; 60:81–9.
[38] Kipp JE, Wong JCT, Doty MJ, Rebbeck CL.Microprecipitation method for preparing submicron suspensions. 2003. US Patent No.6607784.
[39] Radtke M. Pure drug nanoparticles for the formulation of poorly soluble drugs. New Drugs.2001; 3:62–8.
[40] Kozyuk OV. Device and method for creating hydrodynamic cavitation in fFluids. 2003. US Patent No. 6502979.
[41] Junghanns JU, Buttle I, Muller RH, Aranjo IB, Silva AK, Egito ES, Damasceno BP. Solemuls technology: A way to overcome the drawback of parenteral administration of insoluble drugs.Pharm Dev Technol 2007;12:437-45.
[42] Saffie-Siebert R, Ogden J, Parry-Billings.Nanotechnology approaches to solving the problems of poorly soluble drugs. Drug Discovery World. 2005; 6: 71-6.
[43] Discher. D. Shape Effects of Filaments versus Spherical particles in flow and drug delivery. Nat Nanotech. 2007; 2:249–55.
[44] Rana S, Gallo A, Srivastava RS, Misra RD. On the suitability of nanocrystalline ferrites as a magnetic carrier for drug delivery: Functionalization, conjugation and drug release kinetics. Acta Biomat. 2007; 3:233–42.
- Resumen ##plugins.themes.ojsPlusA.frontend.article.viewed##: 65 ##plugins.themes.ojsPlusA.frontend.article.times##
- IJPS_Volume 6_Issue 3_Pages 149-162 (English) ##plugins.themes.ojsPlusA.frontend.article.downloaded##: 13 ##plugins.themes.ojsPlusA.frontend.article.times##